Xeris Biopharma Holdings, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -91.14M-122.72M-94.66M-62.26M-54.84M
Share-based Compensation 8.27M11.38M12.16M10.72M18.36M
Deferred Taxes -1.42M-1.25M-2.27M
Gains from Investment Securities 0.06M0.53M0.47M20.04M3.73M
Cash from Operations -80.56M-95.53M-102.89M-47.02M-36.98M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles -0.08M0.55M10.84M10.84M10.84M
Amortization of Deferred Charges 0.98M1.00M1.60M2.21M3.01M
Depreciation & Amortization (CF) 1.47M1.33M1.40M1.50M1.23M
Change in Working Capital
Change in Receivables 2.18M6.24M13.37M8.37M1.22M
Change in Inventory 5.14M7.42M7.46M14.80M8.78M
Change in Account Payables -2.49M5.53M-4.32M6.96M-9.61M
Change in Accured Expenses 3.20M12.56M-11.38M-5.86M3.65M
Other Working Capital Changes -0.93M-3.29M3.89M7.54M1.67M
Investing Activities
Capital Expenditures 0.38M1.08M
Acquisitions 38.47M
Change in Acquisitions & Divestments 74.75M103.60M34.98M40.00M40.24M
Cash from Investing Activities -27.41M97.96M34.46M-6.00M4.88M
Financing Activities
Other financing activities 5.60M0.05M4.88M1.19M
Cash from Financing Activities 126.06M27.25M127.47M-1.61M36.17M
Additional items
Exchange Rate Effect -0.02M-0.00M
Change in Cash 18.08M29.67M59.04M-54.64M4.07M
Free Cash Flow -80.94M-96.62M-102.89M-47.02M-36.98M
Net Cash Flow 18.10M29.68M59.04M-54.64M4.07M